Harrow (HROW) announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis – Byooviz, an FDA-approved biosimilar referencing Lucentisi, and Opuviz, an FDA-approved biosimilar referencing Eyleaii.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls
- Video: Capricor plunges after CRL, Performance Foods up after seeing interest
- Harrow initiated with an Overweight at Cantor Fitzgerald amid path to growth
- Harrow initiated with an Overweight at Cantor Fitzgerald
- Harrow Health Approves Key Proposals at Annual Meeting